Frontiers in Endocrinology,
Journal Year:
2021,
Volume and Issue:
12
Published: March 12, 2021
Background
Two
recurrent
TERT
(telomerase
reverse
transcriptase)
promoter
mutations,
C228T
and
C250T,
have
been
reported
in
thyroid
carcinomas
were
correlated
with
high-risk
clinicopathological
features
a
worse
prognosis.
Although
far
more
frequent
the
poorly
differentiated
undifferentiated
cancer,
mutations
play
significant
role
on
PTC
recurrence
disease-specific
mortality.
However,
prevalence
varies
considerably
through
studies
it
is
uncertain
if
these
differences
are
due
to
population
variation
or
methodology
used
detect
mutations.
In
this
study
we
aim
compare
three
different
strategies
PTC.
Methods
DNA
was
isolated
from
formalin-fixed
paraffin-embedded
(FFPE)
specimens
89
40
paired
lymph
node
metastases.
The
of
hot
spot
C250T
assessed
FFPE
samples
using
TaqMan
SNP
genotyping
assays.
Random
tested
by
Sanger
Sequencing
droplet
digital
PCR
(ddPCR).
Results
general,
16
out
(18%)
14
(35%)
metastases
harbored
assay.
sequencing,
performed
random
selected
samples,
failed
four
that
positive
Remarkably,
ddPCR
assay
allowed
detection
six
harbor
very
low
mutant
allele
frequency
(≤
2%)
negative
both
genotype
Sequencing.
Conclusion
This
observed
good
concordance
among
methodologies
when
high
percentage
mutated
alleles
present.
analysis
demonstrated
limit
for
alleles.
Therefore,
may
be
higher
than
previously
reported,
since
most
conventionally
sequencing.
efficient
characterization
genetic
alterations
as
preoperative
postoperative
diagnostic,
risk
stratification
patient
individualized
treatment
decisions,
mainly
highly
heterogeneous
tumors,
require
sensitive
specific
approaches.
Journal of Personalized Medicine,
Journal Year:
2021,
Volume and Issue:
11(3), P. 237 - 237
Published: March 23, 2021
Bladder
cancer
(BC)
is
characterized
by
high
incidence
and
recurrence
rates
together
with
genomic
instability
elevated
mutation
degree.
Currently,
cystoscopy
combined
cytology
routinely
used
for
diagnosis,
prognosis
disease
surveillance.
Such
an
approach
often
associated
several
side
effects,
discomfort
the
patient
economic
burden.
Thus,
there
essential
demand
of
non-invasive,
sensitive,
fast
inexpensive
biomarkers
clinical
management
BC
patients.
In
this
context,
liquid
biopsy
represents
a
very
promising
tool
that
has
been
widely
investigated
over
last
decade.
Liquid
will
likely
be
at
basis
selection
precision
medicine,
both
in
terms
treatment
choice
real-time
monitoring
therapeutic
effects.
Several
different
urinary
have
proposed
BC,
including
DNA
methylation
mutations,
protein-based
assays,
non-coding
RNAs
mRNA
signatures.
review,
we
summarized
state
art
on
available
tests
concerning
their
potential
applications
detection,
prognosis,
surveillance
response
to
therapy.
Biosensors and Bioelectronics X,
Journal Year:
2022,
Volume and Issue:
13, P. 100245 - 100245
Published: Nov. 7, 2022
The
accurate
detection
of
potential
biomarkers
in
body
fluids
is
a
vital
step
the
early
specific
diseases,
monitoring
effective
treatment,
and
development
modern
drugs.
In
recent
years,
superiority
biosensors
has
been
highlighted
because
their
inherent
advantages
such
as
cost-effectiveness,
much
friendlier
preparation
determination
steps,
portability,
fast
response
time.
With
introduction
nanomaterials
into
biosensing
fields,
analytical
characteristics
have
improved
dramatically.
primary
reasons
for
using
are
signal
amplification
sensitivity
enhancement.
Other
biosensor
features,
selectivity,
resolution,
time,
linearity,
repeatability,
robustness,
biocompatibility,
stability
can
also
be
by
functionalized
nanomaterials.
Increasing
surface
area,
efficient
immobilization
biomolecules,
catalysis
electrochemical
optical
events
lowing
activation
energy,
accelerating
electron
transfer,
separation
biomolecule's
conjugates
pre-concentration
analyte,
labeling
bioreceptors
considered
most
significant
biosensors.
This
review
provides
comprehensive
overview
results
importance
New
strategies
enhancing
features
systems
analyzed
detail.
Ultimately,
current
challenges
prospects
were
discussed
well.
International Journal of Urology,
Journal Year:
2023,
Volume and Issue:
31(3), P. 208 - 219
Published: Nov. 15, 2023
Abstract
Bladder
cancer
is
a
common
urological
with
high
recurrence
rate
that
requires
long‐term
follow‐up,
and
early
detection
positively
affects
prognosis.
To
date,
the
initial
diagnosis
follow‐up
for
bladder
rely
on
cystoscopy,
which
an
invasive
expensive
procedure.
Therefore,
urinary
markers
of
have
attracted
research
attention
decades
to
reduce
unnecessary
cystoscopies.
Urine,
in
continuous
contact
cancer,
considered
suitable
fluid
providing
tumor
information.
Urinary
cytology
only
widely
used
marker
clinical
practice;
however,
it
has
poor
sensitivity
low‐grade
tumors;
indicating
need
novel
markers.
Considerable
been
conducted
this
topic
over
years,
resulting
complex
landscape
wide
range
markers,
including
protein‐,
exfoliated
cell‐,
RNA‐,
DNA‐,
extracellular
vesicle‐based
Although
some
these
approved
by
U.S.
Food
Drug
Administration
are
commercially
available,
their
use
practice
limited.
facilitate
application,
potential
must
withstand
prospective
trials
be
easy
patients
clinicians
understand
utilize
context.
This
review
provides
comprehensive
overview
currently
available
recently
reported
promising
cancer.
Additionally,
challenges
prospects
implementation
treatment
were
discussed.
